mabthera-ra.co.uk

racentral.co.uk

Home - healthcare professional

http://www.racentral.co.uk/home-healthcare-professional.html

Click here to view the RoACTEMRA website. Click here to view the RoACTEMRA PI. Click here for important upcoming dates for your calendar. News and updates in RA and GPA/MPA. Find out more on the latest news and updates in the RA therapy area. Click here to view the MabThera website. Click here to view the MabThera PI. Roche data on file RXUKMABR00484, 2014; Roche data on file RXUKACTE00042, 2014; Hochberg M. Epidemiol Rev 1981;3:27-44. This website is designed solely for UK Health Care professionals.

roactemra.co.uk

REMISSION IS THE GOAL-NOT TO USE

http://www.roactemra.co.uk/home/remission/remission-is-the-goal_old.html

REMISSION IS THE GOAL. REMISSION IS THE GOAL. Is a 1.2 DAS28 reduction good enough? A small improvement isn’t enough. Remission is the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). Click here to view the NICE guidelines. 2013 NICE Quality Standards in RA. Your patients’ pathway (NICE Quality Standards 33, 2013). Got a question about RoACTEMRA? Check out our FAQs. We use cookies to give you a better experience&...

roactemra.co.uk

REMISSION IS THE GOAL

http://www.roactemra.co.uk/home/remission/remission-is-the-goal.html

REMISSION IS THE GOAL. REMISSION IS THE GOAL. Is a 1.2 DAS28 reduction good enough? A small improvement isn’t enough. Remission should be the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). A small improvement isn’t enough. Remission is the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). 2013 NICE Quality Standards in RA.

roactemra.co.uk

EFFICACY SC

http://www.roactemra.co.uk/home/efficacy/efficacy_sc.html

Nearly 4 times more patients achieved remission with RoACTEMRA IV monotherapy compared with HUMIRA monotherapy (Gabay et al. 2013)*. RoACTEMRA now offers efficacy in achieving remission with the convenience and flexibility of subcutaneous injection (RoACTEMRA SC SmPC, 2014). 67% of patients were MTX naïve. Can I take my RoACTEMRA at home? Is RoACTEMRA subcut as effective as IV? Could I reach remission with RoACTEMRA subcut? Summary of Product Characteristics. Click here to view RoACTEMRA’s SC SmPC. Befor...

roactemra.co.uk

REMISSION IS THE GOAL

http://www.roactemra.co.uk/home/remission.html

REMISSION IS THE GOAL. REMISSION IS THE GOAL. Is a 1.2 DAS28 reduction good enough? A small improvement isn’t enough. Remission should be the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). A small improvement isn’t enough. Remission is the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). 2013 NICE Quality Standards in RA.

roactemra.co.uk

TREATMENT ACCESS

http://www.roactemra.co.uk/home/treatment_access.html

Patients should be offered the treatment option that maximises their chance of sustained remission. NICE recommends RoACTEMRA in combination with methotrexate as a treatment option for adult RA patients with active disease (NICE TA247, 2012) if:. The disease has responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). The disease has responded inadequately to one or more TNF inhibitor treatments and to MabThera. NICE are currently reviewing the clinical and cost effectivenes...

roactemra.co.uk

PATIENT ID

http://www.roactemra.co.uk/home/patient-id/patient-id.html

Methotrexate (MTX) is a standard of care in RA, and a well-established guideline recommended therapy (Smolen et al. 2014). It is the initial treatment choice for both active RA, and also in combination with biologics for DMARD-IR patients (Smolen et al. 2014). But MTX is not appropriate for everyone (Choquette et al. 2012). We just can’t take our MTX anymore, and we might not tell you. Why I might not take my MTX. Click here to order our non-adherence discussion guide. Click here for more information.

roactemra.co.uk

NEWSLETTER SUBSCRIPTION

http://www.roactemra.co.uk/home/NEWSLETTER_SUBSCRIPTION1/newsletter_subscription1.html

Want to stay informed? Sign up to our RA Newsletter. For this purpose please supply the following information. Personal Information collected on this form will only be used for the purposes highlighted above and will not be disclosed to any third party without your written consent. The information will be kept securely and will be kept no longer than necessary. All information, including any 'sensitive data' will be held and processed within the terms of the Data Protection Act 1998. I am not a HCP.

roactemra.co.uk

SAFETY

http://www.roactemra.co.uk/home/safety0.html

Established safety and tolerability profile. Safety and tolerability profile demonstrated over 4.6 years (Genovese et al. Starting treatment of any type can be a daunting prospect for patients. With RoACTEMRA, you can reassure your patients that they are taking a medication with an established safety profile, gathered from extensive clinical trial data and long-term patient use (Genovese et al. Adverse events and infections. For further information on adverse events, please consult the full SmPC.